Sanofi Myeloma Drug Shines But Darzalex Dominates Still

 
• By Kevin Grogan

While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.

Swimmer
Sanofi has a lot of ground to make up in the multiple myeloma space • Source: Shutterstock

More from ASCO

More from Conferences